美国Nabi Biopharmaceuticals       
美国Nabi生物制药公司研发的一种用于治疗尼古丁成瘾和预防复吸疫苗NieVax（尼古丁接合疫苗）获得FDA授予的快通道审批地位。该疫苗将在第二季度进入Ⅱ期概念验证临床试验阶段，包括300位患者，试验结果将于2007年下半年得出。在未来几年里，戒烟市场将发生明显变化。
PentaStaph （五金黄色葡萄球菌疫苗）

Nabi Biopharmaceuticals is focused on developing a series of first and second generation products that address unmet medical needs and offer opportunities in our core business areas: nicotine addiction and gram-positive bacterial infections.

Driven by our clinical development programs, we are focused on building value and are seeking partners for our vaccine programs: NicVAX® (Nicotine Conjugate Vaccine) and PentaStaph™ (Staphylococcal Polysaccharide Conjugate and Toxoid Vaccine). Our headquarters is located in Rockville, Maryland along with our Research and Development facility.